Cite
APA Citation
Martin-Blondel, G., Marcelin, A., Soulié, C., Kaisaridi, S., Lusivika-Nzinga, C., Dorival, C., Nailler, L., Boston, A., Melenotte, C., Gaube, G., Choquet, C., Liblau, R., Carrat, F., Yordanov, Y., & , (2022). outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study). Journal of infection, 84(6), e101–e104. http://access.bl.uk/ark:/81055/vdc_100155152990.0x000052